FORT LAUDERDALE, Fla. — Susvimo was noninferior to monthly ranibizumab and provided comparable vision and controlled retinal thickness through 96 weeks, according to data from the Archway trial.
At the Retina World Congress, Aleksandra Rachitskaya, MD, presented end-of-study results from the phase 3 trial, which explored the safety and efficacy of Susvimo (ranibizumab injection, Genentech) in patients with neovascular age-related macular degeneration.
“The Port Delivery System (PDS) is a continuous intravitreal delivery of a customized formulation of ranibizumab,” she said. “The